Revenue and profits of CRO Business up substantially. Strong growth driven by the overall industry-wide trend of streamlining operations and accelerating R&D activities
Efforts on "time-value creation" that help maximize benefits in clients starting to gain traction
Set new record-high strong orders received in H1
２．Full-year Forecasts and Future Direction
Revise up full-year guidance based on H1 results and current business environments
Expect favorable business environment for CRO Business to continue in H2
Medium- to long-term management perspective is a key to achieve our goal of becoming
"DANTOTSU" (best by far) CRO in the industry.
３．Initiatives to Enhance Corporate Value : SDGs/ESG
Undertake "visualization" of corporate activities through enhanced disclosure and IR/PR activities
Set SDGs Committee and publish first sustainability report
Continue to enhance corporate value as industry leader in initiatives for SDGs/ESG
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
Original document
Permalink
Disclaimer
Shin Nippon Biomedical Laboratories Ltd. published this content on 04 November 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 04 November 2021 03:31:10 UTC.
SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. is a Japan-based company mainly engaged in the provision of clinical trials and drug development services for pharmaceutical companies. The Company has four business segments. The Preclinical segment is engaged in the verification of the effectiveness and safety of new drugs by conducting tests on experimental animals, cells and bacteria. The Clinical segment is engaged in the verification of the effectiveness and safety of test articles on human. The Translational Research segment is involved in the research and development of pharmaceutical products and related technology, as well as the conduction of preclinical and clinical trials, among others. The Others segment is engaged in information collecting business, the sale of environmental analysis equipment, and the operation of accommodation. As of March 31, 2013, the Company had 27 subsidiaries and one associated company.
SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. 
